EAVI2020 Quarterly Newsletter | July 2021
In this issue:
- The EAVI2020 team at Oxford begin clinical trial of novel T cell-based HIV vaccine
- Publications with EAVI2020
- Nathifa and Luis with New Investigator awards at HIVR4P
- Students in Focus revisited
- EAVI2020 at Keystone
Foreword from Robin
It’s been a productive 3 months for EAVI and the consortium with all aspects of the program working to full capacity following previous restrictions related to the COVID pandemic. We are really excited that on 5 July, the EAVI2020 team at University of Oxford started vaccinations of a novel HIV T cell based vaccine candidate as part of a Phase I clinical trial in the UK. The trial’s commencement attracted news coverage on The Telegraph and Evening Standard in the UK, with EAVI’s Prof Tomas Hanke being interviewed for ITV UK national news. Our trials of novel B cell immunogens are progressing well at Imperial College with consortium-wide engagement in the immunological analysis. We are doing the groundwork to initiate additional trials in the coming months.
Congratulations to Nathifa Moyo and Luis Romero for being awarded the New Investigators Awards for their abstracts at HIVR4P. We continue to be very proud and celebrate the successes of our early career researchers, whose work has been integral to EAVI.
In this issue, we’re revisiting some of our EAVI2020 Students in Focus to see what they are up to now and how their training within the EAVI2020 program has enhanced their career development and opportunities. We look forward to continuing to share our updates and news with you as the project enters its final year.
Prof Robin Shattock
EAVI2020 coordinator and on behalf of the EAVI2020 consortium